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Aberrant signaling pathways 
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A stem cell connection
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ABSTRACT 
Medulloblastoma is a highly malignant primary tumor of the central nervous system. It 
represents the most frequent type of solid tumor and the leading cause of death related 
to cancer in early childhood. Current treatment includes surgery, chemotherapy and 
radiotherapy which may lead to severe cognitive impairment and secondary brain tumors. 
New perspectives for therapeutic development have emerged with the identification of 
stem-like cells displaying high tumorigenic potential and increased radio- and chemo-
resistance in gliomas. Under the cancer stem cell hypothesis, transformation of neural 
stem cells and/or granular neuron progenitors of the cerebellum are though to be 
involved in medulloblastoma development. Dissecting the genetic and molecular 
alterations associated with this process should significantly impact both basic and applied 
cancer research. Based on cumulative evidences in the fields of genetics and molecular 
biology of medulloblastomas, we discuss the possible involvement of developmental 
signaling pathways as critical biochemical switches determining normal neurogenesis or 
tumorigenesis. From the clinical viewpoint, modulation of signaling pathways such as TGFb, 
regulating neural stem cell proliferation and tumor development, might be attempted as 
an alternative strategy for future drug development aiming at more efficient therapies and 
improved clinical outcome of patients with pediatric brain cancers. 
Key words: medulloblastoma, neurobiology, signal transduction, stem cells, transforming 
growth factor beta, biological therapy.
Vias de sinalização aberrantes no meduloblastoma: uma conexão com célula-tronco
RESUMO
Meduloblastoma é um tumor maligno do sistema nervoso central (SNC). Na infância, 
representa o tumor sólido mais frequente e a principal causa de morte relacionada ao 
câncer. Tratamentos atuais incluem cirurgia, quimioterapia e radioterapia, que podem 
trazer prejuízos cognitivos e desenvolvimento de tumores secundários. Novas perspectivas 
terapêuticas surgem com a identificação de células-tronco em gliomas, as quais 
apresentam alto potencial tumorigênico e maior resistência à radioterapia e quimioterapia. 
A hipótese das células-tronco tumorais sugere que a transformação de células-tronco e/ou 
progenitores neurais do cerebelo está envolvida no desenvolvimento do meduloblastoma. 
Portanto, analisar alterações genéticas e moleculares envolvidas nesse processo é de 
grande importância na pesquisa básica e aplicada ao câncer. Nesse sentido, discutimos o 
possível envolvimento de vias de sinalização bioquímica críticas a ambos os processos de 
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neurogênese normal ou tumorigênese, com base em evidências atuais na área de genética 
e biologia molecular dos meduloblastomas. Do ponto de vista clínico, a modulação de 
vias de sinalização como a do TGFb, regulando proliferação de célula-tronco neural e 
desenvolvimento tumoral, pode ser uma estratégia alternativa para o desenvolvimento de 
novos medicamentos objetivando-se terapias mais eficientes e melhora do prognóstico 
dos pacientes pediátricos com câncer de SNC.
Palavras-chave: meduloblastoma, neurobiologia, transdução de sinal, células-tronco, fator 
transformador de crescimento beta, terapia biológica.
Medulloblastoma is a malignant embryonic neuroep-
ithelial tumor that account for approximately 16% of all 
pediatric brain tumors1. In the United States, about 540 
new cases are registered each year, with incidence peaking 
between five and ten years of age2,3. According to criteria 
established by the World Health Organization (WHO) in 
2007, medulloblastomas are classified in five histological 
subtypes: classic, desmoplastic, medulloblastoma with ex-
tensive nodularity, anaplastic, and large-cell medulloblas-
toma. The latter two types are highly aggressive tumors 
with similar molecular features and clinical outcomes4. 
The classic symptoms include headaches, vomits and 
nauseas, irritability and ataxia1,3. The five-year survival 
rate for medulloblastoma depends on clinical prognos-
tic criteria, standing around 40% and 70% for “high risk” 
and “standard risk” patients, respectively5.
The choice of treatment modality depends on the age 
of the patient, volume of the remaining tumor, and pres-
ence of metastasis, being based mainly on tumor resec-
tion, craniospinal radiotherapy, and conventional cyto-
toxic therapies. However, the main limitation of current 
treatments is the lack of specificity which often elicits 
long-term adverse effects that include secondary tumors, 
as well as hearing, cognitive, endocrinal and vascular im-
pairment6. Hence, understanding the cellular and molecu-
lar alterations involved in medulloblastoma pathogenesis 
is a critical step toward clinical improvements.
Despite great advances in the knowledge of medullo-
blastoma biology, the origin of this type of primitive neu-
roectodermal tumor is not yet well established. Pediatric 
medulloblastoma typically originates in the midline of the 
cerebellum, growing and compressing the fourth ventricle 
at the beginning of the disease progression. There is a clear 
genetic component in its development. Several techniques 
including karyotyping, fluorescence in situ hybridization, 
and comparative genomic hybridization have been used 
to identify chromosome alterations not only in medullo-
blastomas but also in other types of embryonic brain tu-
mors7. One common genetic alteration in medulloblasto-
ma is a deletion involving the short arm of chromosome 
17, which is detected in 40-50% of primary tumors8,9. 
However, whether this type of deletion correlates with 
poor clinical prognosis still needs to be confirmed10.
More recently, an increasing amount of studies have 
suggested that medulloblastomas may originate from ge-
netic alterations affecting neural stem cells (NSC) and/or 
granule neuron progenitor cells from the cerebellum4,5,11, 
involving aberrant signaling pathways critical to 
neurogenesis12,13. This new interplay between cancer and 
stem cell biology opens new avenues for studying the mo-
lecular events underlying tumorigenesis. The primitive 
nature of medulloblastomas makes them excellent mod-
els for such type of studies, with potential applications 
in oncology.
Medulloblastoma stem Cells 
In the central nervous system (CNS), stem cells self-
renew themselves and give rise to transient proliferating 
progenitors that eventually differentiate into mature neu-
rons and glial cells. All these cellular processes are geneti-
cally regulated by a complex network of molecular inter-
actions. In cancer, it has been postulated that genetic al-
terations in stem cells causing dysfunctional patterns of 
self-renewal and/or differentiation may lead to neoplastic 
stem cells and ensuing tumor development14,15. 
One of the first evidence supporting this cancer stem 
cell (CSC) model of tumorigenesis was reported in acute 
myeloid leukemia (AML)16. After implanting into immu-
nodeficient mice a subset of leukemic cells with typical 
normal hematopoietic stem cell phenotype, the authors 
observed development of secondary AML that pheno-
typically resembled the original tumor cells found in the 
patient.
In solid tumors, CSC were first identified in breast 
cancer17 based on the expression of CD44, a marker as-
sociated with normal mammary ductal stem cells. As ob-
served in AML, when a small subpopulation of CD44+ 
cells was injected in immunodeficient mice, new tumors 
with histopathological features similar to the original 
specimen were developed. The secondary tumors were 
comprised by both CD44– and CD44+ cells. In contrast, 
no tumors were observed in animals injected with CD44– 
breast tumor cells. 
Soon after the report of CSC in breast cancer, the 
CSC hypothesis was also proposed for the origin of high 
grade tumors from the CNS such as glioblastoma mul-
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tiforme18 and medulloblastoma15. Singh and colleagues19 
were the first to identify and isolate populations of CSC 
in medulloblastomas. Intracranial injection of medullo-
blastoma cells expressing the transmembrane glycopro-
tein CD133 were capable of generating new tumors in 
immunodeficient mice15. As little as 100 CD133+ cells 
were enough to develop new tumors with anatomo-path-
ological characteristics that closely resembled those of the 
original tumor. On the other hand, injections of up to 105 
CD133– cells did not have the same tumor initiating ca-
pability. Since then, CD133 has been used as a marker of 
human CSC in brain tumors15,19, in addition to being one 
of the hallmarks of normal neural stem cells. 
Another hypothesis for the origin of medulloblasto-
mas involves fully differentiated and mature cells acquir-
ing a primitive, multipotent phenotype during neoplas-
tic transformation. Thus far, no data supporting this hy-
pothesis has been provided for embryonal brain tumors11. 
However, the recent discovery of iPS cells (induced pluri-
potent stem cells) demonstrated that ectopic expression 
of a few pluripotency-related genes is sufficient to gener-
ate embryonic stem-like cells from fibroblasts, which do 
become undifferentiated and tumorigenic20, supporting 
the above concept.
Although the cellular nature of medulloblastomas is 
still in dispute, it is known that some molecular path-
ways activated during neurogenesis are genetically al-
tered in CNS tumors21. Moreover, evidences based on 
aberrant cerebellar development indicate that popula-
tions of granule neuron precursor cells and the cellu-
lar signaling pathways that regulate their development 
might be involved in the formation of different subtypes 
of medulloblastomas4,5.
Molecular pathways and tumorigenesis
Normal neural development depends on the activa-
tion of membrane receptors by growth factors and sub-
sequent transduction of these messages through intrac-
ellular signaling pathways. Some of these pathways, for 
instance, control the expansion of granular neurons dur-
ing normal embryonic and early post-natal development 
of the cerebellum4. There are several studies in the liter-
ature reporting a possible role of these same pathways in 
the development of CNS neoplasias, including embryon-
ic tumors7 (Figure).
Studies carried out with murine models of medullo-
blastoma suggest that tumors may be originated from pre-
cursors of granular cells known as granular cell progen-
itors (GCP). During normal development, Purkinje cells 
signal GCP to initiate proliferation through Sonic hedge-
hog (SHH) glycoprotein secretion. Afterwards, GCP exit 
cell cycle and are directed to the inner portion of external 
granular layer (EGL) where differentiation and migration 
through Bergmann’s glia fibers are initiated to constitute 
Figure. Main signaling pathways involved in medulloblastoma development. The SHH, NOTCH, WNT and 
TGFb pathways are highly active during neurogenesis. Under pathological conditions, aberrant signaling 
may disrupt the delicate balance among GCP proliferation, migration, and differentiation processes, con-
tributing to tumorigenesis.
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the internal granular layer (IGL). All these steps in granu-
lar cell development are orchestrated by different and in-
teracting molecular pathways. Under pathological condi-
tions, aberrant signaling disrupting this delicate balance 
of GCP proliferation, migration, and differentiation may 
contribute to medulloblastoma development21-23.
The Sonic Hedgehog-Patched (SHH-PTCH) path-
way is the major mitogenic regulator of cerebellar EGL 
cells24. During cerebellar development, SHH glycopro-
tein is mainly produced by Purkinge neurons. Secreted 
SHH binds to PTCH receptor expressed in EGL precur-
sor cells. After release of Smoothened (SMOH) inhibi-
tion, the pathway is activated resulting in transcription of 
target genes such as those encoding the PTCH and GLI 
transcription factors. In mice, blockage of SHH signaling 
pathway with antibodies reduces the amount of differen-
tiated granular cells25. Although, cell proliferation is nor-
mal in the cerebellum of Gli1 knockout mice, medullo-
blastoma can be induced by exogenous SHH26.
The role of SHH in granular cell proliferation is direct-
ly connected to cell cycle control, since SHH was shown 
to induce the expression of CYCLIN D1 and D2 during 
development27. This effect is mediated by MYCN28, which 
is expressed in EGL cells during clonal expansion in vivo 
and is up-regulated in vitro following SHH treatment. On 
the other hand, MYCN specific inactivation in progenitor 
neural cells leads to a smaller and disorganized cerebel-
lum with reduced cellular density in the IGL29.
Mutations in genes encoding key mediators of the 
SHH-PTCH pathway (PTCH, SUFU, and SMOH) were 
described in 25% of sporadic human medulloblasto-
mas30. PTCH mutation in germ line cells leads to a Gor-
lin’s syndrome, familial disorder characterized by occur-
rence of medulloblastomas, basal cell carcinomas, and 
rhabdomyosarcomas31,32. Recently, Yang et al.33 provid-
ed direct evidences that aberrant SHH signaling in stem 
cells can originate medulloblastomas. PTCH deletion in 
knockout Ptcc/c mouse pluripotent stem cells induces its 
expansion. Interestingly, only stem cells that differentiate 
into the granular cell lineage continue cell division until 
tumor development. The increased production of granular 
neuron progenitors during pos-natal development leads 
to a rapid tumor formation, with 100% of animals suc-
cumbing to medulloblastoma within three to four weeks.
In addition to SHH, NOTCH and WNT are other ex-
amples of proteins that modulate pathways controlling 
proliferation and differentiation of cerebellar granular 
cells. Both pathways are highly active during cerebellum 
development21. About 15% of medulloblastomas present 
mutations affecting the WNT transduction signal31,34. Mu-
tations in WNT pathway genes have also been identified 
in sporadic medulloblastomas related to tumor incidence 
in Turcot syndrome, a familial syndrome of brain tumors35. 
TGFβ: a new player in 
medulloblastoma development?
Transforming growth factor beta (TGFβ) and its sig-
naling pathway is frequently involved in cell growth, em-
bryogenesis, differentiation, morphogenesis, extracellu-
lar matrix formation, wound healing, immune response 
and apoptosis in a wide variety of cells. This pathway also 
regulates homeostasis and wound repair in adult tissues, 
including the CNS36,37.
The TGFβ superfamily consists of more than 100 dif-
ferent proteins, such as activins and inhibins, bone mor-
phogenetic proteins (BMP), veg-1, the Drosophila decap-
entaplegic complex, and Mullerian-inhibiting substance. 
Thus far, more than 40 members of this superfamily have 
been described in mammals38,39 as being involved in var-
ious physiological and pathophysiological processes of 
the brain. All three isoforms TGFβ1, TGFβ2 and TGFβ3 
are expressed in neurons and glial cells36. The respective 
TGFβ receptors are expressed in almost every mamma-
lian cells, including cancer cells40,41.
In adult healthy CNS, TGFβ2 and TGFβ3 are ubiqui-
tous and usually co-expressed in the CNS42. TGFβ1 ex-
pression, however, is lower and predominantly found in 
the meninges and choroid plexus. This particular mem-
ber of the TGFβ superfamily plays a central role in coor-
dinating complex cellular responses in the injured CNS 
and has been associated with beneficial as well as detri-
mental activities regarding tissue repair43. 
Up-regulation and activation of TGFβ1 pathway in the 
CNS have been reported after lesions caused by acute in-
sults such as stroke and traumatic brain injury or events 
leading to neurodegeneration42. Accordingly, TGFβ1 ex-
pression in the brain tends to increase with aging44 and 
is up-regulated in some neurological disorders such as 
Alzheimer45, Parkinson46 and Creutzfeldt-Jacob diseas-
es47, amyotrophic lateral sclerosis48, in addition to auto-
immune disorders such as multiple sclerosis. Under such 
conditions, TGFβ1 could either be involved in gliosis or 
protection of mature neurons at the expense of generat-
ing new ones49. 
Acute up-regulation of TGFβ1 after brain injury may 
be beneficial due to its positive effect on neurogenesis50,51. 
However, when TGFβ1 expression levels remain chron-
ically elevated, it may affect the cell cycle of neural pro-
genitor cells and inhibit neurogenesis by prolonging G1 
and/or increasing cell cycle exit49,52. 
A similar effect on neurogenesis occurs during normal 
mammalian CNS development, when TGFβ has been re-
ported to inhibit neural stem cell proliferation. In cancer, 
however, this TGFβ mediated cell growth control seems 
to be bypassed39. Resistance to growth inhibition can be 
detected in malignant glioma cells with functionally ac-
tive TGFβ receptors53. Moreover, silencing of TGFβ ex-
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pression by interfering RNA has been reported to inhib-
it glioma cell migration and invasiveness and extinguish 
glioma cell tumorigenicity in vivo54. Indeed, TGFβ may act 
as an oncogene during tumor progression. In medullo-
blastoma, the effects of TGFβ have been associated with 
mitogenic stimulation55. Stimulation of the TGFβ signal-
ing pathway can further promote metastasis through its 
role in the epithelial-to-mesenchymal transition56. Fur-
thermore, TGFβ is well known by its anti-inflammatory 
and immunosuppressive properties and might as well fa-
vor tumor growth by inhibiting the immune surveillance 
against cancer cells22. Indeed, both TGFβ1 and TGFβ2 
have been reported to be involved in development and 
progression of high-grade gliomas57.
Due to its pro tumorigenic properties, modulation of 
TGFβ signaling pathway is currently under investigation 
as a therapeutic strategy in gliomas58. Noteworthy, there 
is some evidence that BMPs exert anti-proliferative effects 
in medulloblastomas. Production of BMP2 after stimula-
tion with retinoids has been demonstrated to cause apop-
tosis in medulloblastoma cells59. In addition, Rios et al.60 
reported that BMP2 is able to suppress SHH-induced pro-
liferation of granule cell precursors, which are considered 
as putative cells of origin in some cases of medulloblasto-
ma. Therefore, in addition to inhibiting TGFβ, stimulation 
of BMPs could also be explored as a therapeutic approach 
in medulloblastomas. However, as members of the TGFβ 
superfamily play important roles in a wide variety of bi-
ological processes, attempts to modulate TGFβ signaling 
in medulloblastomas still require extensive studies in ex-
perimental models before clinical testing.
CONCLUSION
Cumulative findings in the fields of cancer genetics 
and cell biology support a close connection between sig-
naling pathways controlling stem cell biology and tum-
origenesis. The role of SHH, NOTCH, WNT, and TGFβ 
pathways in normal neurogenesis and development of 
primary brain tumors illustrates this concept. Indeed, 
primitive malignant embryonic tumors such as medullo-
blastomas constitute one practical study subject to under-
stand mechanisms by which cancer stem cells are gener-
ated. Identification of genetic alterations leading to neo-
plastic transformation of neural stem cells and knowledge 
of critical regulators determining the intrinsic properties 
of medulloblastoma stem cells should be of great value. 
It could help refine the development of new cancer drugs 
and enhance the efficiency of molecular therapy and tu-
mor targeting strategies. Under the cancer stem cell hy-
pothesis context, the dual role of TGFβ signaling in neu-
ral stem cell growth control and medulloblastoma devel-
opment makes it an interesting pathway to be further in-
vestigated along this clinical development road.
REFERENCES
1. Rood BR, MacDonald TJ, Packer RJ. Current treatment of medulloblastoma: 
recent advances and future challenges. Sem Oncol 2004;31:666-675.
2. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathological and molecular 
markers of prognosis: toward a new disease risk stratification for medullo-
blastoma. J Clin Oncol 2004;22:984-993.
3. Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current 
clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract 
Oncol 2007;4:295-304.
4. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Ann 
Rev Pathol Mech Dis 2008;3:341-365.
5. Carlotti Jr CG, Smith C, Rutka JT. The molecular genetics of medullo-
blastoma: an assessment of new therapeutic targets. Neurosurg Rev 2008; 
31:359-369.
6. Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and 
future therapeutic approaches. Neurotherapeutics 2009;6:570-586.
7. Gilbertson R. Paediatric embryonic brain tumours: biological and clinical 
relevance of molecular genetic abnormalities. Eur J Cancer 2002;38: 
675-685.
8. Nicholson J, Wickramasinghe C, Ross F, Crolla J, Ellison D. Imbalances of 
chromosome 17 in medulloblastomas determined by comparative ge-
nomic hybridization and fluorescence in situ hybridization. Mol Pathol 
2000; 53:313-319.
9. Steichen-Gersdorf E, Baumgartner M, Kreczy A, Maier H, Fink FM. Deletion 
mapping on chromosome 17p in medulloblastoma. Br J Cancer 1997;76: 
1284-1287.
10. McCabe MG, Ichimura K,. Pearson DM, et al. Novel mechanisms of gene 
disruption at the medulloblastoma isodicentric 17p11 breakpoint. Genes 
Chromo Cancer 2009;48:121-131.
11. Fan X, Eberhart CG. Medulloblastoma stem cells. J Clin Oncol 2008;26: 
2821-2827.
12. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like 
cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 
66:7445-7452.
13. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medullo-
blastoma subgroups that are enriched for specific genetic alterations. J 
Clin Oncol 2006;24:1924-1931. 
14. Nakano I, Kornblum HI. Brain tumor stem cells. Pediatr Res 2006;9:54-58. 
15. Sigh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour 
initiating cells. Nat Publis Group 2004;432:396-401.
16. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hier-
archy that originates from a primitive hematopoietic cell. Nat Med 1997;3: 
730-737.
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Pro-
spective identification of tumorigenic breast cancer cells. Proc Natl Acad 
Sci U S A 2003;100:3983-3988.
18. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumori-
genic, stem-like neural precursors from human glioblastoma. Cancer Res 
2004;64:7011-7021.
19. Sigh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in 
human brain tumors. Cancer Res 2003;63:5821-5828.
20. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells 
from adult human fibroblasts by defined factors. Cell 2007;131:861-872.
21. Marino S. Medulloblastoma: developmental mechanisms out of control. 
Trends Mol Med 2005;11:17-22.
22. Fogarty MP, Kessler JD, Wechsler-Reya RJ. Morphing into cancer: the role 
of developmental signaling pathways in brain tumor formation. J Neu-
robiol 2005;64:458-475. 
23. Knoepfler PS, Kenney AM. Neural precursor cycling at sonic speed: N-Myc 
pedals, GSK-3 brakes. Cell Cycle 2006;5:47-52.
24. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors, 
Ann Rev Neurosci 2001;24:385-428.
25. Dahmane N, Ruiz i Altaba A. Sonic hedgehog regulates the growth and pat-
terning of the cerebellum. Development 1999;126:3089-3100.
26. Weiner HL, Bakst R, Hurlbert MS, et al. Induction of medulloblastomas in mice 
by sonic hedgehog, independent of Gli1. Cancer Res 2002;62:6385-6389.
27. Ciemerych MA, Kenney AM, Sicinska E, et al. Development of mice ex-
pressing a single D-type cyclin. Genes Dev 2002;16:3277-3289.
28. Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog 
signaling promotes proliferation in developing cerebellar granule neuron 
precursors, Development 2003;130:15-28.
Arq Neuropsiquiatr 2010;68(6)
952
Medulloblastomas: a stem cell connection
Rodini et al.
29. Knoepfler PS, Cheng PF, Eisenman RN. N-myc is essential during neuro-
genesis for the rapid expansion of progenitor cell populations and the in-
hibition of neuronal differentiation. Genes Dev 2002;16:2699-26712.
30. Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway 
genes in medulloblastoma. Genes Chromo Cancer 2000;27:44-51.
31. Chidambaram A, Goldstein AM, Gailani MR, et al. Mutations in the human 
homologue of the Drosophila patched gene in Caucasian and African-
American nevoid basal cell carcinoma syndrome patients. Cancer Res 1996; 
56:4599-4601.
32. Fukushima Y, Oka H, Utsuki S, Iwamoto K, Fujii K. Nevoid basal cell car-
cinoma syndrome with medulloblastoma and meningioma: case report. 
Neurol Med Chir 2004;44:665-668.
33. Yang ZJ, Ellis T, Markant SL, et al. Medulloblastoma can be initiated by de-
letion of patched in lineage-restricted progenitors or stem cells. Cancer 
Cell 2008;14:135-145.
34. Baeza N, Masuoka J, Kleihues P, Ohgaki H. AXIN1 mutations but not dele-
tions in cerebellar medulloblastomas. Oncogene 2003;22:632-636.
35. Hamilton SR, Liu B, Parsons RE, et al. The molecular basis of Turcot‘s syn-
drome. N Engl J Med 1995;332:839-847. 
36. Bottner M, Krieglstein K, Unsicker K. The transforming growth factor-betas: 
structure, signaling, and roles in nervous system development and func-
tions. J Neurochem 2000;75:2227-2240.
37. Unsicker K, Krieglstein K. TGF-betas and their roles in the regulation of 
neuron survival. Adv Exp Med Biol 2002;513:353-374. 
38. Massague J. TGF-beta signal transduction. Ann Rev Biochem 1998;67: 
753-791.
39. Aigner L, Bogdahn U. TGF-beta in neural stem cells and in tumors of the 
central nervous system. Cell Tissue Res 2008;331:225-241.
40. Massague J, Weis-Garcia F. Serine/threonine kinase receptors: mediators of 
transforming growth factor beta family signals. Cancer Surv 1996;27: 41-64.
41. Golestaneh N, Mishra B. TGF-b, neuronal stem cells and glioblastoma. On-
cogene 2005;24:5722-5730.
42. Flanders KC, Ren RF, Lippa CF. Transforming growth factorbetas in neuro-
degenerative disease. Prog Neurobiol 1998;54:71-85.
43. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1: 
169-178.
44. Nichols NR. Glial responses to steroids as markers of brain aging. J Neu-
robiol 1999;40:585-601.
45. Issazadeh S, Mustafa M, Ljungdahl A, et al. Interferon gamma, interleukin 4 
and transforming growth factor beta in experimental autoimmune enceph-
alomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central 
nervous system and lymphoid cells. J Neurosci Res 1995;40:579-590.
46. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T. Trans-
forming growth factor-beta 1 levels are elevated in the striatum and in ven-
tricular cerebrospinal fluid in Parkinson‘s disease. Neurosci Lett 1995;193: 
129-132.
47. Baker CA, Lu ZY, Zaitsev I, Manuelidis L. Microglial activation varies in dif-
ferent models of Creutzfeldt-Jakob disease. J Virol 1999;73:5089-5097.
48. Iłzecka J, Stelmasiak Z, Dobosz B. Transforming growth factor-Beta 1 
(tgf-Beta 1) in patients with amyotrophic lateral sclerosis. Cytokine 2002;20: 
239-243.
49. Buckwalter MS, Yamane M, Coleman BS, et al. TGF-1 Inhibits hippocampal 
neurogenesis. Am J Pathol 2006;169:154-164.
50. Calegari F, Huttner WB. An inhibition of cyclin-dependent kinases that 
lengthens, but does not arrest, neuroepithelial cell cycle induces premature 
neurogenesis. J Cell Sci 2003;116:4947-4955.
51. Battista D, Ferrari CC, Gage FH, Pitossi FJ. Neurogenic niche modulation 
by activated microglia: transforming growth factor beta increases neuro-
genesis in the adult dentate gyrus. Eur J Neurosci 2006;23:83-93.
52. Wachs F, Winner B, Couillard-Despres S, et al. Transforming growth fac-
tor-A1 is a negative modulator of adult neurogenesis. J Neuropathol Exp 
Neurol 2006;65:358-370.
53. Isoe S, Naganuma H, Nakano S, et al. Resistance to growth inhibition by 
transforming growth factor-beta in malignant glioma cells with functional 
receptors. J Neurosurg 1998;88:529-534.
54. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting trans-
forming growth factor-beta enhances NKG2D-mediated antiglioma 
immune response, inhibits glioma cell migration and invasiveness, and 
abrogates tumorigenicity in vivo. Cancer Res 2004;64:7596-7603.
55. Jennings MT, Kaariainen IT, Gold L, Maciunas RJ, Commers PA. TGF beta 1 
and TGF beta 2 are potential growth regulators for medulloblastomas, prim-
itive neuroectodermal tumors, and ependymomas: evidence in support of 
an autocrine hypothesis. Hum Pathol 1994;25:464-475.
56. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat 
Rev Cancer 2002;2:442-454.
57. Kjellman C, Olofsson SP, Hansson O, et al. Expression of TGF-beta isoforms, 
TGF-beta receptors, and SMAD molecules at different stages of human 
glioma. Int J Cancer 2000;89:251-258.
58. Rich JN, Bigner DD. Development of novel targeted therapies in the 
treatment of malignant glioma. Nat Rev Drug Discov 2004;3:430-446.
59. Hallahan AR, Pritchard JI, Chandraratna RA, et al. BMP-2 mediates retinoid-
induced apoptosis in medulloblastoma cells through a paracrine effect. 
Nat Med 2003;9:1033-1038.
60. Rios I, Alvarez-Rodriguez R, Marti E, Pons S. Bmp2 antagonizes sonic hedge-
hog-mediated proliferation of cerebellar granule neurones through Smad5 
signalling. Development 2004;131:3159-3168.
